2004 News

December 21, 2004

Morphotek Appoints Senior Vice President of Clinical Development to Advance Therapeutic Antibody Portfolio
Read More

December 13, 2004

Morphotek Issued U.U. Patent 6,825,038 for Generating Genetically Evolved Mammalian Cells Through the Regulation of Mismatch Repair
Read More

December 1, 2004

Morphotek Announces Second Research Collaboration and License Agreement with Novo Nordisk to Develop High-Titer Cell Lines for the Scalable Manufacturing of Therapeutic Antibodies
Read More

November 17, 2004

Morphotek Honored With Technology Company of the Year Award
Read More

November 15, 2004

Morphotek and SC BioSciences Announce a Business Collaboration for the Marketing of Morphotek's Proprietary Cell Line Evolution Services in Japan
Read More

November 8, 2004

Morphotek Issued U.S. Patent for Generating Genetically Altered Antibody Producing Cell Lines With Improved Antibody Characteristic
Read More

November 7, 2004

Morphotek Announces Collaborative Agreement with Tanox to Develop High-Titer Production Cells for the Manufacturing of Therapeutic Antibodies Using Suppressor of Immunoglobulin Product (SIP) Technology
Read More

September 27, 2004

Morphotek Announces Research and Development Agreement with USAMRID at Fort Detrick for the Development of Antibodies to Detect and Treat Biowarfare Pathogens
Read More

August 10, 2004

Morphotek Signs Development and Clinical Supply Agreement with Baxter for Lead Therapeutic Antibody
Read More

July 19, 2004

Morphotek and Protein Design Labs Announce Broad, Multi-Year Research Cross-License and Commercialization Agreement
Read More

June 1, 2004

Morphotek Issued U.S. Patent for Generating Genetically Enhanced Antigens for Vaccine Development
Read More

April 6, 2004

Morphotek Achieves Collaboration Milestone with the Successful Development of Antibody Cell Line for Centocor
Read More

February 18, 2004

Morphotek Inc. Closes $26 Million Series C Financing
Read More

January 12, 2004

Morphotek Announces Research And Development Agreement With The National Cancer Institute For The Development Of Antibodies For The Treatment Of Pancreatic, Ovarian And Lung Cancer
Read More